Jiangxi Rimag (2522) H1 2026 earnings summary

Executive summary

• H1 revenue rose 9.8% YoY to RMB513.0m, while the period swung to a RMB27.9m net loss from profit of RMB15.8m amid higher operating and share-based payment expenses.

• Imaging solution and digital-intelligent services expanded as imaging centre services contracted; priorities include asset-light expansion, AI and data commercialisation, and ecosystem development.

Financial highlights

• Revenue increased 9.8% YoY to RMB513.0m; gross profit fell 10.4% to RMB122.9m.

• Net loss was RMB27.9m versus profit of RMB15.8m; loss attributable to owners was RMB13.9m versus profit of RMB16.4m.

• Adjusted net loss was RMB5.4m, versus adjusted profit of RMB15.8m; adjusted owner-attributable profit was RMB8.5m, down 48.2%.

• Excluding share-based payment expense, adjusted net loss narrowed from RMB26.3m in H2 2025 to RMB5.4m in H1 2026; adjusted owner-attributable results improved from a RMB12.7m loss to RMB8.5m profit.

Outlook and guidance

• Priorities include deeper imaging specialisation, regional network density, data governance and AI collaboration, human-machine workflows, solution replication and overseas expansion; no numerical guidance was stated.

• Management expects gross profit and margin to improve gradually through refined operations, cost optimisation and a larger mix of higher-margin empowerment products.

• Management expects operating benefits to improve as digital services scale, data assets are monetised and AI capabilities are reused across workflows.

• Mobile healthcare had served over 10,000 patient visits in Beijing, Harbin and Nanyang; management expects the business to move toward scaled growth.